Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Lupin Limited, together with its subsidiaries, operates as a pharmaceutical company in India and internationally. It engages in the drug discovery, development, production, marketing, and sale of various branded and generic formulations, biosimilars, over-the-counter and specialty drugs, and active pharmaceutical ingredients (APIs). The company offers formulations for use in the therapeutic areas of anti-tuberculosis, diabetes management, cardiovascular, chronic obstructive pulmonary diseases, asthma, gynecology and women's health, central nervous system, oncology, immunology, genomics, metabolic disorders, dermatology, urology, pediatrics, gastrointestinal, anti-infective, and nonsteroidal anti-inflammatory drug therapies, as well as engages in the bio clinical research activities. It operates through network consists of labs, LupiMitra collection centers, and pick-up points. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for LUPIN
Revenue projections for LUPIN

LUPIN's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 0.000000
forwardPE 22.071232
debtToEquity 31.500000
earningsGrowth 0.519000
revenueGrowth 0.119000
grossMargins 0.683080
operatingMargins 0.232270
trailingEps 80.720000
forwardEps 81.760000

Lupin Limited's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
LUPIN's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for LUPIN.
Lupin Limited's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
LUPIN's forward EPS surpassing its trailing EPS signals that the company is anticipated to be more profitable this year than last. This growth expectation highlights LUPIN's potential for increased earnings and a stronger financial performance in the upcoming year.

Price projections:

Price projections for LUPIN
Price projections for LUPIN

LUPIN's price projections have consistently been revised higher, indicating growing confidence in the company's future potential. Analysts appear more optimistic about LUPIN's ability to generate strong results going forward.

Recommendation changes over time:

Recommendations trend for LUPIN
Recommendations trend for LUPIN


A recent buy bias from analysts toward LUPIN indicates strong confidence in the stock's future performance. This could encourage investors to park their money in LUPIN, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.